SEC Comment Letter 0000000000-24-009482 to AEON Biopharma, Inc. (AEON) (CIK 0001837607) (AEON)
AEON Biopharma, Inc. (AEON) (CIK 0001837607)
Date: Aug. 19, 2024 · CIK: 0001837607 · Accession: 0000000000-24-009482
AI Filing Summary & Sentiment
File numbers found in text: 333-281562
Letter
August 19, 2024 Alex Wilson Chief Legal Officer AEON Biopharma, Inc. 5 Park Plaza, Suite 1750 Irvine, CA 92614 Re:AEON Biopharma, Inc. Registration Statement on Form S-3 Filed August 15, 2024 File No. 333-281562 Dear Alex Wilson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:B. Shayne Kennedy, Esq.
Show Raw Text
August 19, 2024
Alex Wilson
Chief Legal Officer
AEON Biopharma, Inc.
5 Park Plaza, Suite 1750
Irvine, CA 92614
Re:AEON Biopharma, Inc.
Registration Statement on Form S-3
Filed August 15, 2024
File No. 333-281562
Dear Alex Wilson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:B. Shayne Kennedy, Esq.